Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of ≤10 ng/mL and biopsy Gleason score of ≤6, and their influence on PSA progression-free survival after radical prostatectomy

BJU International

Volumn 97, Issue 6, 2006, Pages 1173-1178

  Weckermann, Dorothea ^a   Goppelt, Marcus ^a   Dorn, Robert ^a   Wawroschek, Friedhelm ^b   Harzmann, Rolf ^a  

^a KLINIKUM AUGSBURG   (Germany)

^b KLINIKUM OLDENBURG   (Germany)

Author keywords

Disease progression; Lymphatic metastases; Prostatectomy; Prostatic neoplasm

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; INCIDENCE; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; UROLOGY;

ADULT; AGED; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PELVIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY;

EID: 33745215410     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06166.x     Document Type: Article

References (23)

1. Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002 168: 514 8
2. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002 167: 1681 6
3. Wawroschek F, Vogt H, Wengenmair H et al. Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol Int 2003 70: 303 10
4. Wawroschek F, Vogt H, Weckermann D, Wagner T, Harzmann R. The sentinel lymph node concept in prostate cancer - first results of gamma probe-guided sentinel lymph node identification. Eur Urol 1999 36: 595 600
5. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958 53: 457
6. Partin AW, Kattan MW, Subong ENP et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997 277: 1445 51
7. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001 58: 843 8
8. Golimbu M, Morales P, Al-Askari S, Brown J. Extended pelvic lymphadenectomy for prostatic cancer. J Urol 1979 121: 617 20
9. Stone NN, Stock RG, Unger P. Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques. J Urol 1997 158: 1891 4
10. Janetschek G. Pelvic lymph node dissection in prostate cancer. Curr Opin Urol 2005 15: 65 7
11. Jeschke S, Nambirajan T, Leeb K, Ziegerhofer J, Sega W, Janetschek G. Detection of early lymph node metastases in prostate cancer by laparoscopic radioisotope guided sentinel lymph node dissection. J Urol 2005 173: 1943 6
12. Corvin S, Schilling D, Anastasiadis AG, Bares R, Stenzl A, Kuczyk M. Radioisotope guided pelvic lymph node dissection for prostate cancer staging. Eur Urol Suppl 2005 4: 25 7
13. Weckermann D, Wawroschek F, Harzmann R. Is there a need for pelvic lymph node dissection in low risk prostate cancer patients prior to definitive local therapy? Eur Urol 2005 47: 45 51
14. Burkhard FC, Schumacher M, Thalmann GN, Studer UE. Is pelvic lymphadenectomy really necessary in patients with a serum prostate-specific antigen level of <1 0 ng/mL undergoing radical prostatectomy for prostate cancer? BJU Int 2005 95: 275 8
15. Catalona WJ, Miller DR, Kavoussi LR. Intermediate-term survival results in clinically understaged prostate cancer patients following radical prostatectomy. J Urol 1988 140: 540 3
16. Bader P, Spahn M, Huber R, Echtle D, Frohneberg D. Limited lymph node dissection in prostate cancer may miss lymph node metastases and determines outcome of apparently pN0 prostate cancer. Eur Urol Suppl 2004 3: 16 A55
17. Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003 169: 849 54
18. Daneshmand S, Quek ML, Stein JP et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004 172: 2252 5
19. Allaf ME, Palaputtu GS, Trock BJ, Carter HB, Walsh PC. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004 172: 1840 4
20. DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML. The extent of lymphadenectomy for pTXN0 prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 2005 173: 1121 5
21. Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol 1999 161: 1223 8
22. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer. N Engl J Med 1999 341: 1781 8
23. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at 10 years of EST 3886. J Urol 2003 169 ( Suppl. 4 396, A1480